In this article, we will look at the Top 12 Blue Chip Stocks to Buy At 52-Week Lows.On September 30, Elyse Ausenbaugh, Head of Investment Strategy at JPMorgan Wealth Management, joined CNBC for an interview to discuss the current market rally. She noted that there is a strong momentum going forward in 2025, which is likely to continue in 2026 as well. She sees improvements in the macroeconomic environment and anticipates powerful tailwinds from significant investments in AI.She highlighted that the current ...

Amgen Inc. (NASDAQ:AMGN) is one of the best large cap value stocks to buy now. On September 26, Bank of America Securities analyst Tim Anderson maintained a Sell rating on Amgen Inc. (NASDAQ:AMGN) and set a price target of $272.00. Is Amgen (AMGN) a Safe Bet for Income Investors in Cheap Quarterly Dividend Stocks? The same day, Amgen Inc. (NASDAQ:AMGN) announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. Management reported that the planned investment is a ...

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. Biopharmaceutical giant Amgen said it plans to invest $650 million to increase drug production at its Juncos, Puerto Rico, facility, as part of a larger effort to expand its U.S. manufacturing network. The investment is expected to create nearly 750 jobs, including in construction and highly-skilled manufacturing roles. It also will support advanced techn ...

Group 1: AI Investment Opportunity - Artificial intelligence is considered the greatest investment opportunity of our lifetime, with a strong emphasis on the urgency to invest now [1] - Wall Street is investing hundreds of billions into AI, but there is a critical question regarding the energy supply needed to support this technology [2] - AI data centers consume as much energy as a small city, leading to concerns about power grid strain and rising electricity prices [2] Group 2: Company Overview - A specific company, largely overlooked by AI investors, is positioned to benefit from the increasing demand for energy due to AI [3] - This company owns critical energy infrastructure assets and is involved in the U.S. LNG exportation sector, which is expected to grow under the current administration's energy policies [7] - The company is debt-free and has a significant cash reserve, amounting to nearly one-third of its market cap, making it financially robust [8] Group 3: Market Position and Valuation - The company is trading at less than 7 times earnings, which is considered undervalued compared to its potential in the AI and energy sectors [10] - It also holds a substantial equity stake in another AI-related company, providing indirect exposure to multiple growth engines without a premium [9] - Wall Street is beginning to take notice of this company as it benefits from various market trends without the high valuations typical of the sector [8] Group 4: Future Outlook - The future of energy is closely tied to AI, with a focus on the need for infrastructure to support this technological shift [6] - The influx of talent into the AI sector is expected to drive rapid advancements and innovative ideas, further solidifying AI's role in the future economy [12] - The combination of AI, energy infrastructure, and favorable government policies presents a unique investment landscape with significant upside potential [14]

We recently compiled a list of the 12 Most Undervalued Dow Stocks to Buy According to Analysts. Amgen Inc. is one of them. Amgen Inc. (NASDAQ:AMGN), a leading biotechnology company specializing in innovative therapeutics for complex cancers and serious illnesses, is strengthening its U.S. manufacturing footprint with a major $650 million expansion announced in September 2025. The project will upgrade the biologics facility in Juncos, Puerto Rico, incorporating advanced technologies to enhance production e ...

While biopharmaceutical giant Amgen (AMGN) managed to eke out a modest gain on Friday, the past week has been rough, with AMGN stock losing 4%. Adding insult to injury, the equity is rated as a 72% Strong Sell by the Barchart Technical Opinion indicator. Despite the volatility risks, contrarians could be justified in betting on the healthcare juggernaut.Just like in America’s favorite pastime, the use of sabermetrics doesn’t guarantee that you’ll win baseball games. However, a consistent, empirical framewor ...

Amgen - Amgen plans to invest $650 million to expand its U.S. manufacturing operations in Puerto Rico, creating approximately 750 jobs [2][9] - This investment is a direct response to President Trump's announcement of a 100% tariff on pharmaceutical products not manufactured domestically, effective October 1 [2][9] - Since late 2017, Amgen has invested over $40 billion in U.S. manufacturing and R&D, including a $900 million expansion in Ohio and a $1 billion investment in North Carolina earlier this year [3][9] Starbucks - Starbucks is closing 434 North American stores by the end of September, reducing its store count from 18,734 to 18,300 [4][9] - The closures are part of a restructuring plan aimed at improving financial stability and customer experience, with 900 non-retail employees being laid off [5][9] - Despite the closures, Starbucks plans to increase its North American store count in the next fiscal year and redesign over 1,000 locations [5][9] China's Industrial Sector - China's industrial profits surged by 20.4% year-over-year in August, a significant recovery from a -1.5% decline in July [6][9] - The cumulative industrial profit for January-August increased by 0.9% to ¥4.69 trillion, indicating potential stabilization in the manufacturing sector [6][7][9] JPMorgan and Alibaba - JPMorgan Chase increased its stake in Alibaba from 6.81% to 12.29% on September 22, signaling bullish sentiment towards the tech sector [8][10] - This move reflects growing confidence in Alibaba and the broader tech sector, driven by global AI developments and increasing domestic computing power demands [11]

Market Overview - Wall Street is on track to end the week higher, with the Dow up approximately 360 points, S&P 500 up about 0.6%, and NASDAQ up about 0.4% [2][3] - The Dow is up 0.8% for the day, while the NASDAQ is down about 0.67% for the week, marking the worst performance since August 1st [3][4] - The 10-year Treasury yield has increased by one basis point, indicating a trend of rising yields since Wednesday [5] Inflation and Federal Reserve Insights - The core Personal Consumption Expenditures (PCE) index for August is reported at 2.9%, consistent with July's figures, suggesting inflation is stable but not accelerating [11][12] - Federal Reserve officials express concerns about persistent inflation, with some suggesting that productivity gains from AI could mitigate inflationary pressures [13][14] - The next jobs report is anticipated to be crucial for the Fed's decision-making regarding interest rates, especially if it indicates a soft job market [14][16] Tariff Implications - President Trump's new tariff threats, including a 50% duty on certain pharmaceuticals and furniture, are causing concern in the affected industries, particularly in the furniture sector [17][18] - Companies like Wayfair and RH are adapting by diversifying their supply chains away from China, while pharmaceutical companies with U.S. manufacturing facilities are less affected by the tariffs [19][20] - The impact of these tariffs on inflation and economic growth is expected to vary by industry, with some sectors facing more significant challenges than others [22][23] Digital Asset Treasuries - Over 180 public companies have added Bitcoin to their balance sheets, indicating a growing trend in digital asset treasuries [74] - Breer Holdings is rebranding as Soulmate, focusing on a Solana-based digital asset treasury, highlighting the shift towards blockchain technologies that can handle high transaction volumes [75][87] - The emergence of digital asset treasuries is seen as a response to previous regulatory challenges and market inefficiencies, with a focus on building actual infrastructure to support these assets [91][92] Weight Loss Drug Market - The GLP-1 weight loss drug market is projected to potentially reach $100 billion annually within the next decade, driven by innovations and expanded indications beyond obesity [106][108] - Current injectable GLP-1 drugs show weight loss efficacy between 12% to 20%, with oral formulations expected to be slightly less effective [110][111] - Eli Lilly and Novo Nordisk dominate the market, but Amgen is also making strides with late-stage trials for its weight loss drug [105][116]

Hours after President Donald Trump imposed 100% tariffs on pharmaceuticals with exemptions for companies building manufacturing plants in the U.S., Eli Lilly (NYSE:LLY) and Amgen (NASDAQ:AMGN) announced their latest investments in their home country. Lilly announced the opening of its ...

Core Viewpoint - The Trump administration's announcement of a potential 100% tariff on pharmaceutical products not manufactured in the U.S. has significant implications for the pharmaceutical industry, creating uncertainty and prompting companies to increase domestic manufacturing investments [1][2]. Group 1: Tariff Announcement and Market Reaction - President Trump threatened a 100% tariff on branded or patented pharmaceutical products starting October 1 unless companies establish manufacturing plants in the U.S. [1] - Following the announcement, pharmaceutical stocks remained stable, with the SPDR S&P Pharmaceutical ETF (XPH) rising by 1.6% and the VanEck Pharmaceutical ETF (PPH) increasing by 0.6% [3]. - Analysts suggest that larger biopharmaceutical companies may not be significantly affected due to ongoing U.S. facility construction, but smaller companies could face exposure [2]. Group 2: Company Responses and Investments - Pharmaceutical companies have announced over $350 million in U.S. manufacturing investments, with Amgen committing to expand its U.S. manufacturing by $650 million following the tariff threat [4]. - Amgen's CEO emphasized the importance of increasing capacity to deliver innovative medicines and creating high-quality jobs in biotechnology [5]. - Companies like Argenx, AbbVie, and Novartis highlighted their U.S. manufacturing capabilities during recent earnings calls, indicating a strong domestic presence [6]. Group 3: Broader Implications and Investigations - The tariff threat may serve as a negotiating tactic related to the ongoing Section 232 investigation into the impact of imports on national security [7]. - A separate Section 232 investigation into medical devices was announced, causing a nearly 2% decline in the medical-products industry group [8]. - Analysts predict that the medical device investigation may lead to additional tariffs, similar to the pharmaceutical tariffs, but the timing remains uncertain [9][10].